August 1900



AEC-NASA TECH BRIEF



AEC-NASA Tech Briefs describe innovations resulting from the research and development program of the U.S. AEC or from AEC-NASA interagency efforts. They are issued to encourage commercial application. Tech Briefs are published by NASA and may be purchased, at 15 cents each, from the Clearinghouse for Federal Scientific and Technical Information, Springfield, Virginia 22151.

Experimental Study and Evaluation of Radioprotective Drugs

A two-part study has been conducted to survey the general aspects of the testing and evaluation of radioprotective drugs and to use these testing and evaluation methods to ascertain the radioprotective effects of certain compounds administered orally and by I.V.

Interest in drugs which protect against the damaging or lethal effects of radiation is of moment because of the hazards of radiation therapy, the nuclear industry, nuclear war, and space travel. This study was concerned solely with compounds that are administered before exposure. The effectiveness of the compounds were evaluated for protection against lethal effects which occur within 30 days after irradiation.

The evaluation techniques to determine an agent's capacity to decrease an organism's sensitivity to ionizing radiation are essentially the same as those used in the evaluation of other types of drugs. Such factors as drug dosage, administration route, detoxification rate, tissue distribution, therapeutic index, time after administration, and species, strain, sex, nutrition, and environmental status of the experimental animal are common to almost all testing techniques.

Most of the techniques that are unique to the evaluation of radioprotective drugs are referable to the damaging agent, the ionizing radiation. Radiation may be of different qualities, of electromagnetic or of particle nature, in a wide variety of energies, of variable dose rates, etc. The response of the organism will, in most cases, be markedly affected by these factors of quality, energy and dose rate, and the efficacy of a protective compound will thus depend to a large extent on the nature of the radiation. Specifically studied are the sources of radiation, choice of radiation dose, choice of animals, administration of drugs, the toxicity of protective agents, and the types of protective drugs.

The remainder of the study concerned the description of experiments designed to study the effectiveness of orally administered aminothiols in lethally irradiated mice. It has been known for a long time that these drugs were radioprotective when injected intravenously, but their effectiveness after oral administration was generally reported as poor. The mice were subjected to single, total-body exposures of 775 rads of X-rays. This dose produced 100% mortality in control mice, the deaths occurring between the tenth and eighteenth day after exposure. When mice received solutions of cysteine or 2-mercaptoethylamine (MEA) in 20% gum arabic 1 hour prior to exposure, survival increased in proportion to the dose. With MEA, 100% survival occurred after 750 mg/kg; 90% survival was observed in mice pretreated with 2700 mg/kg of cysteine. These doses are 3 to 5 times as much as is required to produce the same degree of protection after intravenous injection.

Notes:

- This study has been reported in Methods of Evaluating Radioprotective Drugs, by D. E. Smith and J. F. Thomson in Methods of Drug Evaluation, North-Holland Publishing Company (1966).
- 2. Inquiries concerning this innovation may be directed to:

Office of Industrial Cooperation Argonne National Laboratory 9700 South Cass Avenue Argonne, Illinois 60439 Reference: B68-10320 Source: D. E. Smith and J. F. Thomson, Biological and Medical Research Division (ARG-10196)

(continued overleaf)

This document was prepared under the sponsorship of the Atomic Energy Commission and/or the National Aeronautics and Space Administration. Neither the United States Government nor any person acting on behalf of the United States Government assumes any liability resulting from the use of the information contained in this document, or warrants that the use of any information, apparatus, method, or process disclosed in this document may not infringe privately owned rights.

Patent status:

Inquiries about obtaining rights for commercial use of this innovation may be made to:

Mr. George H. Lee, Chief Chicago Patent Group U.S. Atomic Energy Commission Chicago Operations Office 9800 South Cass Avenue Argonne, Illinois 60439